Articles published by QIAGEN N.V.

< Previous 1 2 Next >
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Commits to Reduce Carbon Emissions by Setting Science-Based Target to Reach Net Zero by 2050
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN and BD Settle Patent Infringement Lawsuit
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Reports Strong Results for Third Quarter and First Nine Months Of 2021
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN to Enter the DAX – Germany’s Leading Stock Market Index
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN and GT Molecular Collaborate to Offer a Complete SARS-CoV-2 Wastewater Detection Solution Based on QIAcuity Digital PCR Technology
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN Reports Full Results for Q2 and H1 2021
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN announces preliminary Q2 2021 results exceeding outlook, updates full-year 2021 outlook for declining COVID-19 test trends and plans new $100 million share repurchase program
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN’s NeuMoDx™ HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.